Naccarelli Gerald V, Antzelevitch Charles, Wolbrette Deborah L, Luck Jerry C
Division of Cardiology, Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Curr Opin Cardiol. 2002 Jan;17(1):19-23. doi: 10.1097/00001573-200201000-00003.
The Brugada syndrome describes a subgroup of patients at risk for the occurrence of ventricular fibrillation who have no definable structural heart disease associated with a right bundle branch block conduction pattern and ST-segment elevation in the right precordial leads. This syndrome is caused by genetic defects in the alpha subunit of the sodium channel. This defect causes a reduction in the sodium channel current, which accentuates the epicardial action potential notch leading to ST-segment elevation. Sodium channel blockers can potentiate these findings and screen for patients with intermittent baseline electrocardiographic findings. Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator.
Brugada综合征描述了一组有发生室颤风险的患者,这些患者没有与右束支传导阻滞图形及右胸前导联ST段抬高相关的明确结构性心脏病。该综合征由钠通道α亚基的基因缺陷引起。这种缺陷导致钠通道电流减少,从而加剧心外膜动作电位切迹,导致ST段抬高。钠通道阻滞剂可增强这些表现,并用于筛查有间歇性基线心电图表现的患者。由于这类患者预后较差,有症状的患者应接受植入式心脏复律除颤器治疗。